(Q35757913)

10 August 2017

1 reference

title

Current status of the utilization of antiepileptic treatments in mood, anxiety and aggression: drugs and devices (English)

1 reference

10 August 2017

2

Anna Lembke

1 reference

10 August 2017

John J Barry

1

1 reference

10 August 2017

Kim D Bullock

series ordinal

3

1 reference

10 August 2017

language of work or name

1 reference

1 January 2004

1 reference

Clinical EEG and Neuroscience

10 August 2017

published in

1 reference

10 August 2017

volume

35

1 reference

10 August 2017

issue

1

1 reference

10 August 2017

page(s)

4-13

1 reference

Potential Mechanisms of Action of Lamotrigine in the Treatment of Bipolar Disorders

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Current research on rapid cycling bipolar disorder and its treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

A review of randomized, controlled clinical trials in acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

New perspectives in the treatment of acute mania: a single case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Lamotrigine and the treatment of mania in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Topiramate in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Antiepileptic drugs in psychiatry-focus on randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Clinical Factors in Lithium Carbonate Prophylaxis Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

A Double-Blind, Placebo-Controlled, Prophylaxis Study of Lamotrigine in Rapid-Cycling Bipolar Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Use of topiramate, a new anti-epileptic as a mood stabilizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Effect of carbamazepine on pain scores of unipolar depressed patients with chronic pain: a trial of off-on-off-on design

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Comprehensive review of the psychiatric uses of valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Treatment of social phobia with gabapentin: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Placebo-controlled study of gabapentin treatment of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Kindling versus quenching. Implications for the evolution and treatment of posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Posttraumatic stress disorder in vietnam veterans clinical and EEG findings; possible therapeutic effects of carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Valproate therapy for chronic, combat-induced posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Antiepileptic drugs in posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

A double-blind placebo-controlled crossover study of phenytoin in individuals with impulsive aggression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Sodium valproate in the treatment of aggressive behavior in patients with dementia--a randomized placebo controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Efficacy and tolerability of carbamazepine for agitation and aggression in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

The evolving place of vagus nerve stimulation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Vagus nerve stimulation therapy summary: five years after FDA approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

The co-morbidity of depression and epilepsy: epidemiology, etiology, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Earlier use of adjunctive vagus nerve stimulation therapy for refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Therapeutic mechanisms of vagus nerve stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Vagus nerve stimulation therapy: a research update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Electroconvulsive therapy in the treatment of neuropsychiatric conditions and transcranial magnetic stimulation as a pathophysiological probe in neuropsychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Transcranial magnetic stimulation in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Repetitive transcranial magnetic stimulation for the treatment of depression. Systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: a pilot study of acute safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

Right prefrontal TMS versus sham treatment of mania: a controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F155005940403500107

10.1177/155005940403500107

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference